CSTL Q3 2021 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CSTLCastle Biosciences, Inc.

$772M

Q3 2021 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$23M+54.3% YoY

Gross Profit

$19M80.8% margin

Operating Income

-$12M-50.3% margin

Net Income

-$12M-50.2% margin

EPS (Diluted)

$-0.47

QoQ Revenue Growth

+3.2%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$7M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$434M

Total Liabilities

$22M

Stockholders' Equity

$412M

Cash & Equivalents

$363M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$23M	$15M	+54.3%
Gross Profit	$19M	$13M	+48.9%
Operating Income	-$12M	-$4M	-202.8%
Net Income	-$12M	-$5M	-156.9%